Eyenovia Past Earnings Performance
Past criteria checks 0/6
Eyenovia's earnings have been declining at an average annual rate of -4.9%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been growing at an average rate of 25.9% per year.
Key information
-4.9%
Earnings growth rate
26.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 25.9% |
| Return on equity | -302.9% |
| Net Margin | -719,859.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Is Eyenovia (NASDAQ:EYEN) Weighed On By Its Debt Load?
Jan 30
Is Eyenovia (NASDAQ:EYEN) Using Debt In A Risky Way?
Oct 14Is Eyenovia (NASDAQ:EYEN) Using Debt Sensibly?
Jun 27Does Eyenovia (NASDAQ:EYEN) Have A Healthy Balance Sheet?
Oct 25Eyenovia gains as H.C. Wainwright initiates with Buy on pipeline potential
Oct 05Eyenovia names Michael Rowe as new CEO
Jul 27New Forecasts: Here's What One Analyst Thinks The Future Holds For Eyenovia, Inc. (NASDAQ:EYEN)
Apr 03Earnings Beat: Eyenovia, Inc. (NASDAQ:EYEN) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Mar 31Eyenovia: I Can See You Better - Now
Mar 04Eyenovia: Reassessing After The FDA Moves The Goalposts
Nov 23Eyenovia: FDA Setback Is Big Opportunity For Investors
Nov 08Eyenovia: Can You See Me Now?
Oct 21Is Eyenovia (NASDAQ:EYEN) A Risky Investment?
Sep 16Eyenovia updates on late-stage program for presbyopia therapy
Jun 15Eyenovia: Recent MicroLine Data, October MydCombi PDUFA Date Bode Well For Value Creation
Jun 02Eyenovia announces new $25M credit facility with Silicon Valley Bank
May 10Stuart Grant Just Bought A Sprinkling of Shares In Eyenovia, Inc. (NASDAQ:EYEN)
Mar 09Revenue & Expenses BreakdownBeta
How Eyenovia makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -27 | 14 | 12 |
| 30 Sep 23 | 0 | -25 | 13 | 10 |
| 30 Jun 23 | 0 | -25 | 14 | 10 |
| 31 Mar 23 | 0 | -26 | 14 | 11 |
| 31 Dec 22 | 0 | -28 | 15 | 12 |
| 30 Sep 22 | 10 | -19 | 15 | 13 |
| 30 Jun 22 | 10 | -17 | 14 | 13 |
| 31 Mar 22 | 12 | -15 | 13 | 13 |
| 31 Dec 21 | 14 | -13 | 12 | 14 |
| 30 Sep 21 | 6 | -20 | 10 | 14 |
| 30 Jun 21 | 6 | -19 | 9 | 14 |
| 31 Mar 21 | 4 | -20 | 8 | 14 |
| 31 Dec 20 | 2 | -20 | 8 | 13 |
| 30 Sep 20 | 0 | -21 | 8 | 13 |
| 30 Jun 20 | 0 | -20 | 7 | 13 |
| 31 Mar 20 | 0 | -21 | 7 | 14 |
| 31 Dec 19 | 0 | -21 | 7 | 14 |
| 30 Sep 19 | 0 | -22 | 7 | 15 |
| 30 Jun 19 | 0 | -22 | 8 | 14 |
| 31 Mar 19 | 0 | -20 | 7 | 13 |
| 31 Dec 18 | 0 | -17 | 6 | 11 |
| 30 Sep 18 | 0 | -13 | 5 | 9 |
| 30 Jun 18 | 0 | -10 | 3 | 7 |
| 31 Mar 18 | 0 | -7 | 3 | 5 |
| 31 Dec 17 | 0 | -5 | 1 | 4 |
| 30 Sep 17 | 0 | -4 | 1 | 3 |
| 31 Dec 16 | 0 | -4 | 1 | 3 |
Quality Earnings: EYEN is currently unprofitable.
Growing Profit Margin: EYEN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EYEN is unprofitable, and losses have increased over the past 5 years at a rate of 4.9% per year.
Accelerating Growth: Unable to compare EYEN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EYEN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-6.8%).
Return on Equity
High ROE: EYEN has a negative Return on Equity (-302.93%), as it is currently unprofitable.